產(chǎn)品名稱： GMI-R1大鼠小膠質(zhì)細(xì)胞、 GMI-R1大鼠小膠質(zhì)細(xì)胞、 GMI-R1大鼠小膠質(zhì)細(xì)胞、 GMI-R1大鼠小膠質(zhì)細(xì)胞；

prolonged overall survival compared with patients with a low IO-score (discovery cohort: HR, 0.29; 95% CI 0.15 to 0.56; p=0.003; validation cohort: HR, 0.32; 95% CI 0.10 to 1.05; p=0.04). Taken together, our results indicated the potential of IO-score as a biomarker for immunotherapy in patients with gastrointestinal cancers.Background: Cutaneous adverse drug reactions (CADRs) are drug-induced skin reactions with or without systemic involvement,